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Introduction
Gene therapy involves the use of
nucleic acids (DNA or RNA) for the
treatment,cureorpreventionofhuman
disorders. Depending on the type of
disease, this can be achieved either by
delivery of a functional, therapeutic
gene as a substitute for the defective or
missing endogenous counterpart or by
reducing the levels of a harmful defec-
tive gene product, using various
sophisticated tools including naked
oligonucleotides, viral and non‐viral
vectors.
Gene therapy initially focused on
orphan diseases with detrimental
monogenetic defects, such as primary immunodeﬁciencies
(PID), for which this treatment was considered to be the last,
if not the only therapeutic option. The increasing number of
successful trials has driven the development of gene therapy
approaches to include more widespread applicability, for
example, in cancer and chronic or progressive diseases such
as heart failure, neurodegenerative or metabolic disorders,
including Parkinson’s and diabetes (Elsner et al, 2012; Jessup
et al, 2011; LeWitt et al, 2011). Although cancer gene therapy
accounts now for the majority of clinical trials worldwide
(January 2013, http://www.wiley.com//legacy/wileychi/
genmed/clinical/), this topic is beyond the scope of this review
and readers are referred to recent reviews on this area (Cronin
et al, 2012; Lam et al, 2013; Park et al, 2012; Russell et al, 2012;
Shen et al, 2012; Wang et al, 2011).
China was the ﬁrst country to introduce a gene based‐drug
(Gendicine®), into the market in 2004. Gendicine is an
adenovirus‐p53 based gene therapeutic approved for the
treatment of patients with head and neck squamous cell
carcinoma (Wilson, 2005). With more than 10,000 treated
patients no overt adverse side effects have been reported for
Gendicine®. However, the therapeutic efﬁcacy of this drug is still
controversial (Sheridan, 2011; Shi & Zheng, 2009). In Europe,
alipogenetiparvovec(alsoknownasGlybera®)wasapprovedfor
the treatment of familial lipoprotein lipase deﬁciency (LPLD) at
the end of 2012, and thus, was the ﬁrst commercially available
gene therapeutic product in the Western world (Büning, 2013;
Miller, 2012; Ylä‐Herttuala, 2012). The marketing authorization
forGlybera®clearlyrepresentsamilestoneinthedevelopmentof
gene therapy as an accessible therapeutic option for LPLD
patients. The Glybera® example also revealed the multiple layers
ofcomplexity that have tobe solved before adrug‐based product
reaches the market. In addition to patent issues, the costs for
adequate production of the advanced therapy medicinal product
(ATMP) according to good‐manufacturing practice (GMP)
requirements are enormous. Moreover, costly and extensive
The ﬁrst gene therapy clinical trials were initiated more than two decades ago. In
the early days, gene therapy shared the fate of many experimental medicine
approaches and was impeded by the occurrence of severe side effects in a few
treated patients. The understanding of the molecular and cellular mechanisms
leading to treatment- and/or vector-associated setbacks has resulted in the
development of highly sophisticated gene transfer tools with improved safety and
therapeutic efﬁcacy. Employing these advanced tools, a series of Phase I/II trials
were started in the past few years with excellent clinical results and no side effects
reported so far. Moreover, highly efﬁcient gene targeting strategies and site-
directed gene editing technologies have beendeveloped and applied clinically. With
more than 1900 clinical trials to date, gene therapy has moved from a vision to
clinical reality. This review focuses on the application of gene therapy for the
correctionofinheriteddiseases,thelimitationsanddrawbacksencounteredinsome
of the early clinical trials and the revival of gene therapy as a powerful treatment
option for the correction of monogenic disorders.
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the absence of clearly deﬁned standards, even in cases where
very similar vector backbones are used. In addition, the review
process and eventual authorization by the respective agencies
adds another layer of complexity as exempliﬁed by the hurdles
encountered during the review process for Glybera® (as
reviewed elsewhere (Bryant et al, 2013)). Thus, there are still
multiple issues to be addressed in gene therapy before gene‐
based products enter routine clinical application to provide safe
and affordable therapeutic drugs for otherwise non‐treatable
overt and chronic diseases.
In vivo and ex vivo gene therapy
Multiple gene delivery systems are available, which can
either provide transient or stable gene transfer. When the
therapeutic effect can be achieved upon expression of a
single gene in post‐mitotic tissue, non‐integrating vector
systems are favoured. Indeed, in one of the ﬁrst in vivo
clinical trials, an attenuated adenovirus‐derived vector was
used for the treatment of ornithine transcarbamylase
deﬁciency (OTCD), an inborn disease of urea synthesis (Raper
et al, 2002). Vector‐ and transgene‐elicited immunoreactions
were initially of concern in the in vivo application of vector
particles, as documented by the death of one out of the 17
subjects treated in the OTCD trial, which was caused by a
massive immune reaction against the capsid of the infused
adenoviral vector (Raper et al, 2003). Meanwhile elaborate
technologies have been developed not only to shield the viral
capsid proteins from recognition by the host immune system,
but to successfully implement clinical trials with non‐integrating
vectors mainly in the area of cancer gene therapy (Cattaneo
et al, 2008; Russell et al, 2012).
For the correction of monogenic disorders in post‐mitotic
tissues, adeno‐associated virus‐derived vectors (AAV) are
currently used, as described in detail later. In combination with
other characteristics such as low inﬂammatory activity, they
have shown to have an excellent safety proﬁle and are therefore
highly attractive tools for in vivo gene therapy. Indeed, Glybera®
is a recombinant AAV for direct intramuscular injection (Fig 1
and Table 1).
In contrast, retroviral vectors are preferred for the stable gene
transfer into proliferating cells, since they have the capability to
integrate into the host cell genome. The current protocols
include cell isolation from the patient followed by their genetic
modiﬁcation outside the body and subsequent re‐introduction
into the patient as an autologous transplant (ex vivo gene
therapy). This lowers the risk of unwanted off‐target effects,
such as toxicity due to ectopic expression of the therapeutic gene
in off‐target organs and excludes germ‐line transmission.
Furthermore, the therapeutic agent can be administered more
robustly since the gene‐based drug is not subject to metabolic or
renal clearance and is less likely to trigger immune responses.
Depending on the protocol, ex vivo gene therapy may even allow
selection, expansion and quality control of the modiﬁed cells
before reinfusion, thus further improving safety and efﬁcacy
(Fig 1).
Pioneering clinical trials have been performed with mobilized
haematopoietic stem cells (HSC) cells, as these cells are easily
isolated from the blood after G‐CSF mobilization. In addition,
procedures to introduce gene‐modiﬁed HSC into patients have
proﬁted from the extensive experience accumulated during
50 years of HSC transplantation (HSCT) (Appelbaum, 2007). In
parallel to HSC, mature blood cells have been extensively used
for a wide variety of gene therapy purposes resulting in a broad
spectrum of applications. Indeed, the ﬁrst application of gene
modiﬁedhaematopoieticcellsintohumanswasperformedatthe
Glossary
Insertional transformation
Vector-induced dysregulation of gene expression at the site of
integration leading to cell immortalization and eventually to
tumourigenesis.
Self‐inactivating (SIN)
Deletions in the U3 region of the 30 long-terminal repeats (LTR) of a
retroviral vector results in a transcriptionally inactive 50LTR upon
reverse transcription reducing the transactivation potential of the
vector. The lack of promoter activity is compensated by an internal
promoter of choice.
Engraftment
Incorporation of graft cells into the host, e.g. transplanted donor
haematopoieticstem cellsengraft in thebone marrow ofthe recipient.
Suicide gene
Agenethatinducesapoptosisuponactivationbyawell-deﬁnedstimulus.
Transgene
Exogenous genes that are delivered by a vector in trans are also
referred to as transgenes.
Cross‐correction
The therapeutic gene product is produced by another cell entity than
the actual cell type affected by the genetic defect.
Primary immunodeﬁciency (PID)
Inherited disorders manifesting in a compromised immune system.
G‐CSF mobilization
Injectionofthecytokinegranulocyte-colonystimulatingfactor(G-CSF)
induces haematopoietic stem cells to translocate from the bone
marrow into the blood, a process called mobilization, and thus can be
isolated by collecting peripheral blood.
Designer nucleases
Artiﬁcial restriction enzymes designed to speciﬁcally target a locus of
interest, e.g. to trigger gene correction or gene disruption via induction
of cellular DNA repair mechanisms.
Induced pluripotent stem cells (iPSC)
Cells derived from non-pluripotent somatic cells that have been
reprogrammed to a pluripotent state upon exposure to certain
reprogramming agents. They thereby gain the capacity to differentiate
into various tissue types similar to the natural pluripotent embryonic
stem cells.
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tumour inﬁltrating lymphocytes to track the persistence and
localization of the cells after re‐infusion into patients with
advanced melanoma (Rosenberg et al, 1990). Following this
proof of principle, the ﬁrst gene therapy trial aimed at the
correction of an inborn disease was based on the genetic
modiﬁcation of T‐lymphocytes for the treatment of adenosine
deaminase (ADA) deﬁciency (Blaese et al, 1995). T‐lymphocytes
have also been extensively evaluated for autologous adoptive
cell transfer providing transient immunotherapy ranging from
several weeks to more than a decade (Brentjens et al, 2011;
Scholler et al, 2012). For example, a new speciﬁcity can be
introduced into T cells by delivering an endogenous or synthetic
receptor, such as chimeric antigen receptors (CAR), which
recognize an antigen of choice on cancer cells and thus, facilitate
tumour‐cell recognition, ultimately leading to formation of an
armada of activated T cells and killing of target cells. This
approach has been used successfully in clinical trials, for
instance by targeting the B‐lymphocyte restricted surface
molecule CD19 to treat B‐cell leukaemia and lymphoma. In 28
reported cases, this procedure was well tolerated with no
therapy related severe side effects and promising clinical
outcomes including complete remissions (Kalos et al, 2011;
Kochenderfer et al, 2010; Porter et al, 2011). Donor‐derived
T cells have been widely used to induce a graft‐versus‐leukaemia
effectincasesofrelapseafterallogeneicHSCT.However,serious
graft‐versus‐host‐disease (GvHD) is frequently observed in
treated patients leading to impaired quality of life and reduced
survival expectancy, thus limiting the potential of this approach.
The introduction of inducible suicide genes, which can be
activated upon GvHD development, into the T cells allograft
allows for a patient‐speciﬁc modulation of alloreactivity (Di Stasi
etal,2011;Lupo‐Stanghellinietal,2010;Vagoetal,2012).These
approaches have been extensively reviewed elsewhere and will
Patient
IN VIVO
IN VIVO
Isolation of 
hematopoietic target cells
Gene transfer
EX VIVO
EX VIVO
Reinfusion of
  gene-modified cells
+/– BM conditioning
Target cell Vectors
Therapeutic
gene
Figure 1. In vivo and ex vivo gene therapy concepts. For the in vivo application of gene-based drugs, the therapeutic gene is introduced directly into the body
(e.g. muscle, liver) of the patient, while for ex vivo applications, patient cells are ﬁrst isolated from the body, genetically modiﬁed outside the body and
reintroduced into the patient as an autologous transplant (see text for details). BM, bone marrow.
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Brenner, 2012; June et al, 2009; Kalos, 2012; Kershaw
et al, 2013).
Gene therapeutic approaches for skin diseases also offer a
promising and easily accessible cell source for topical in vivo
application (Roos et al, 2009) as well as for ex vivo modiﬁcation
as assessed for instance for epidermolysis bullosa, an inherited
skin disorder of connective tissue (Mavilio et al, 2006). Follow-
ing extremely invasive protocols, hepatocytes are also amenable
to ex vivo gene therapy as they can be isolated from liver,
cultured ex vivo and after genetic modiﬁcation reintroduced into
the patient via the hepatic portal vein. Indeed, one of the earliest
gene therapy trials was conducted by Grossman et al, in 1992 to
treat a patient with familial hypercholesterolemia by genetic
modiﬁcation ex vivo of cultured hepatocytes (Grossman
et al, 1994). With the development of highly efﬁcient vectors
this approach has been largely replaced by the direct injection of
the therapeutic vector into the portal vein, as discussed later.
However, genetic modiﬁcation of HSC remains the major focus
of gene therapy trials for inherited disorders due to the
undeniable achievements in the past, not only in terms of
experience, efﬁcacy, long‐term follow‐up and accessibility, but
also the rapid translation into clinical Phase I/II trials (Table 1).
Primary immunodeﬁciencies in the focus of gene
therapy for monogenic disorders
PIDcomprisesagroup ofrare, inheriteddisorders oftheimmune
systemcausedbydefectsinthedevelopmentand/orfunctionsof
the various cells of the immune system leading to impaired
adaptive and/or innate responses, predisposing patients to
Table 1. Overview of clinical trials mentioned in the text
Target cell/injection Disease Transgene Vector Refs.
Ex vivo T-lymphocytes ADA-SCID ADA Gammaretroviral Blaese et al (1995)
HSC ADA-SCID ADA Gammaretroviral Aiuti et al (2002)
SCID-X1 IL2Rgc Lentiviral Cavazzana-Calvo et al (2000)
WAS WASP ( SIN design) Boztug et al (2010) and
Aiuti et al (2013)
X-CGD gp91
phox Ott et al (2006)
HSC b-Thalassaemia b-Globin SIN-lentiviral Cavazzana-Calvo et al (2010)
HSC X-ALD ABCD1 SIN-lentiviral Cartier et al (2009)
HSC MLD ARSA SIN-lentiviral Biffi et al (2013)
HSC HIV ZFNs targeting CCR5
(knock out)
Adenoviral Burnett et al (2012) and
Lee et al (2013)
Hepatocytes Familial
hypercholesterinemia
LDL receptor Gammaretroviral Grossman et al (1994)
T-lymphocytes B-cell malignancies Anti-CD19 CAR SIN lentiviral Kalos et al (2011),
Kochenderfer et al (2010)
and Porter et al (2011)
SB-transposon Swierczek et al (2012)
Keratinocytes Epidermolysis
bullosa
laminin 5 b3 Gammaretroviral Mavilio et al (2006)
In vivo Intratumoural Head and neck
squamous
cell carcinoma
p53 Adenovirus
(Gendicine)
Wilson (2005) and
Shi & Zheng (2009)
Intramuscular LPLD LPL AAV1 (Glybera) Bryant et al (2013) and
Kastelein et al (2013)
Systemic/portal vein OTCD OTC Adenovirus Raper et al (2002, 2003)
Subretinal LCA RPE65 AAV2 Bainbridge et al, 2008;
Hauswirth et al, 2008;
Maguire et al, 2008
Intracerebral
(subthal. nucl.)
Parkinson’s disease GAD AAV2 Kaplitt et al (2007) and
LeWitt et al (2011)
Intracerebral Canavan disease ASPA AAV2 Leone et al (2012)
Intramuscular,
systemic/portal vein
Haemophila B FIX AAV2 Kay et al (2000)
AAV2, AAV8 Manno et al (2006)
Nathwani et al (2011)
Coronary artery infusion Heart failure SERCA2a AAV1 Jessup et al (2011)
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speciﬁc causative genetic defect (>190), the phenotypes of PIDs
are generally diverse, often overt and result in a highly reduced
life expectancy (Casanova et al, 2008; Fischer, 2003; Gathmann
et al, 2012; Notarangelo, 2010). Transplantation of HSC from
allogeneic HLA‐compatible donors is the treatment of choice for
patients with PID, resulting in long‐term survival of >90% of
patients and effective immune reconstitution. For all others
however, transplantations from mismatched donors are still
associated with a high morbidity and mortality due to
autoimmune and inﬂammatory manifestations, persistent infec-
tions, serious GvHD reactions and graft rejection (Honig
et al, 2006; Mazzolari et al, 2007; Neven et al, 2009; Railey
et al, 2009; Titman et al, 2008). Therefore, genetic modiﬁcation
of the patient’s own HSCs has been considered as an attractive
therapeutic option for patients lacking compatible HSC donors.
Despite their rare overall prevalence (ranging between 1 and 5 in
100,000 inhabitants within Europe) (Gathmann et al, 2012),
monogenetic PIDs have several attributes, which made them
highly attractive for gene therapy: they require the ex vivo
delivery of just one single gene into the HSC, for some PIDs there
isa natural invivo selection for genecorrected cells and there are
well‐established protocols for HSC isolation and transplantation
(Aiuti et al, 2012; Appelbaum, 2007).
A genetic defect can affect the haematopoietic system at
various stages of haematopoiesis leading to a PID (Fig 2). In
some cases disruption in the early stages of lineage commitment
leads to a total lack of cell subsets further downstream, as is the
case in severe combined immunodeﬁciency (SCID). This
disorder can be subdivided according to the underlying genetic
aberration. Currently, gene therapy approaches have mainly
focused on two of the most common types of SCID: the
autosomal recessive inherited enzymatic defect of the ubiqui-
tously expressed adenosine deaminase (ADA‐SCID) that plays
role in the purine salvage pathway, and the dysfunction in
interleukin‐2 (IL‐2) signalling due to mutations in the X‐
chromosomal encoded common gamma chain of the IL‐2
receptor (SCID‐X1; Aiuti et al, 2009; Candotti et al, 2012;
Cavazzana‐Calvo et al, 2012; Fischer et al, 2013; Gaspar, 2012;
Hacein‐Bey‐Abinaetal,2002).Phenotypically,patientssuffering
from these PIDs either lack the lymphocytic compartment
including NK cells or their lymphocytes have impaired function
(Fig 2). These patients are transplanted soon after birth, if a
matched related donor is available. Otherwise, their life
expectancy reaches barely beyond infancy (Gathmann
et al, 2009). Other PIDs manifest further downstream in the
haematopoietic pedigree. In patients with Wiskott–Aldrich
syndrome (WAS), thrombocyte and immune cell (but also all
other mature blood cells) functionalities are impaired due to a
defect in a haematopoietic protein (WASp) responsible for
linking receptor signalling to organization of the actin
cytoskeleton (Notarangelo et al, 2008). Chronic granulomatous
disease (CGD) belongs to the inherited myeloid disorders with
no known deﬁcit in haematopoietic cell numbers. The CGD
phenotype is characterized by the inability of mature phagocytes
to kill ingested microorganisms and eventually manifests as
severe and life‐threatening granuloma and abscess formation
accompanied by hyper‐inﬂammation. The underlying genetic
mutations are manifold and the affected genes encode for
different subunits of the phagocyte NADPH oxidase complex
(gp91
phox, p22
phox, p47
phox, p67
phox, p40
phox; Roos, 1994; Segal
et al, 1992). In most cases ( 70%), the cytochrome b(558) gene
?
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replacement/
cross-
correction
HSC MPP
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MEP
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ALD
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Figure 2. Haematopoiesis and main diseases in
focus of ex vivo HSC gene therapy. The
haematopoieticstemcell(HSC)hasthe abilitytogive
rise to all terminally differentiated haematopoietic
effector cells by passing through various
intermediate precursor stages. Lineage fate is
determined mainly by cytokine proﬁles which drive
development from multipotent progenitors (MPP) to
either oligopotent committed lymphoid or myeloid
progenitors (CLP and CMP, respectively). CLP
eventually provide mature B- and T-lymphocytes,
natural killer (NK) cells and dendritic cells (DC). DC
can also descend from the myeloid lineage. CMP give
rise to megakaryocyte–erythrocyte progenitors
(MEP) and granulocyte–monocyte-progenitor (GMP)
eventually resulting in either erythrocytes (Ery) and
platelet-producing megakaryocytes (Mk) or
monocytes (M) and the different entities of
granulocytes (G), respectively (adapted from
Doulatov et al, 2012). Primary immunodeﬁciencies
(PID) discussed in the text (black) can manifest at
several of these stages as indicated, resulting in
defects affecting only certain cell types or in
complete absence of an entire lineage branch. Gene-
transfer in HSC also offers cell replacement or cross-
correction of storage diseases of the brain, e.g. due to
invading monocytes differentiating into microglia.
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encodes for the catalytic subunit gp91
phox, is affected (van den
Berg et al, 2009). Therefore, delivering gp91
phox as a transgene is
a reasonable approach to treat most of these patients.
The early years of gene therapy
The very ﬁrst approved clinical trial for gene therapy for PIDs
was initiated in 1990 and addressed ADA‐SCID. In this initial
study, two children suffering from ADA deﬁciency were treated
repeatedly by autologous transplantation of T‐lymphocytes that
had been modiﬁed ex vivo with a functional copy of the ADA
cDNA by gammaretroviral vector‐mediated gene transfer. Both
patients responded positively to the treatment as measured by
normalizing T lymphocyte counts in the blood as well as by an
increase in ADA enzyme activity in one patient (Blaese
et al, 1995). However, the phenotype was not entirely reversed
as both patients remained on enzyme replacement therapy
(polyethylene glycol conjugated bovine ADA, PEG‐ADA),
thereby masking the natural in vivo selective advantage of
detoxiﬁcation by gene modiﬁed cells. Nonetheless, this impor-
tant study presented the proof‐of‐concept for the feasibility to
treat a genetic disorder by gene therapy without major side
effects. Due to low efﬁciency of transduction and lack of
sustained engraftment, following studies used improved gene
transfer protocols, slightly altered gammaretroviral vectors and
CD34
þ HSCs as target cells. In addition, a non‐myeloablative
conditioning regimen was implemented to enhance engraftment
of gene‐transduced cells (Aiuti et al, 2002; Carbonaro et al, 2012;
Gaspar, 2012). To date, more than 40 patients with ADA‐
deﬁciency have been treated by gene therapy at different centres
in Italy, the UK and the US with impressive success when
compared to mismatched allogeneic HSCT as all 40 patients are
still alive with excellent reconstitution of immune and metabolic
functions. Moreover, the vast majority of patients (n¼29) has
become independent of PEG‐ADA replacement therapy (Aiuti
et al, 2009, 2002; Candotti et al, 2012; Gaspar et al, 2011). In a
few cases, however, enzyme‐replacement had to be reinitiated
due to low engraftment and/or low peripheral T‐cell counts
caused by deﬁcient thymic support. Gene therapy has been also
highly successful in the absence of myelosuppressive condition-
ing in SCID‐X1 infants according to functional T‐cell reconstitu-
tion. Eighteen out of 20 treated SCID‐X1 children are alive with
full reconstitution of T‐cell immune functions, revealing a
superior success rate (10% mortality rate) than conventional
allogeneic HSCT (25% mortality rate) (Cavazzana‐Calvo
et al, 2000; Fischer et al, 2011; Gaspar et al, 2011; Hacein‐
Bey‐Abina et al, 2002; Sheridan, 2011; Zhang et al, 2013). This
compelling success was favoured by a natural selective
advantage for gene‐corrected cells, as in both types of SCID,
patients are devoid of either all or some lymphocytic lineages
offering empty niches for transplanted cells to engraft. Despite
this selective advantage gene therapy for older SCID‐X1 patients
has beenless successful, most likely reﬂectingthe loss of thymus
regulated T‐cell maturation after puberty and emphasizes that
the age of the patients at the time of treatment is crucial in some
disease contexts. Recent data, however, suggests that non‐
myeloablative conditioning may improve not only T‐cell
reconstitution but also B‐ and NK‐cell recovery in older SCID‐
X1 patients after gene therapy, although the reported follow‐up
in this patient was too short (3 months as of May 2013) to allow
for any conclusive statements (DeRavin et al, 2013).
The resulting enthusiasm in the ﬁeld, however, was
dampened by the occurrence of acute T‐cell lymphoblastic
leukaemia (T‐ALL) in ﬁve SCID‐X1 patients 2–5.5 years after
gene therapy. Four out of these ﬁve patients are in remission
after chemotherapy and in good condition with detectable gene
marking in peripheral blood cells (Cavazzana‐Calvo et al, 2012).
Initiation of transformation was traced back to insertional
activation of the proto‐oncogene LMO2 (LIM domain only 2), a
transcriptional cofactor, which in addition to its role in HSC
development, promotes self‐renewal of committed T cells when
overexpressed thereby facilitating the acquisition of additional
mutations (McCormack et al, 2010). Indeed, in four out of the
ﬁve cases of T‐ALL, additional leukaemia promoting mutations
unrelated to the vector integration event were described
(Cavazzana‐Calvo et al, 2000; Hacein‐Bey‐Abina et al, 2003;
Howe et al, 2008).
The ﬁrst three clinical gene therapy trials for CGD were
initiatedinthelate1990swithlimitedsuccessascomparedtothe
aforementioned trials addressing ADA‐ or SCID‐X1 (Goebel &
Dinauer, 2003; Malech, 1999; Malech et al, 1997). The major
difference was observed in the absence of engrafted gene‐
modiﬁed cells. In the ﬁrst CGD patients (n¼12) treated, <1% of
circulating peripheral blood cells were transgene‐positive a few
months after gene therapy, while in gene therapy trials
addressing other PIDs full reconstitution of the T‐cell compart-
ment was observed in some cases with signiﬁcant (0.1–16%)
gene marking in the myeloid compartment (Aiuti et al, 2007;
Cavazzana‐Calvo et al, 2005), the target compartment in CGD.
Although the protocols were comparable in terms of gene
delivery, culture and transduction conditions, gene‐modiﬁed
cells of CGD patients are not known to have survival and
proliferative advantages over non‐transduced cells, as is the case
in SCID‐X1 and ADA‐SCID, imposing the necessity of (partial)
myeloablation previous to the reinfusion of gene modiﬁed cells
for CGD. Subsequent gene therapy trials addressing X‐CGD used
mild conditioning regimes as exempliﬁed in a 2004 trial initiated
in Frankfurt (Ott et al, 2006). Despite partial conditioning with
low myeloablative regimens, long‐term engraftment of gene
corrected cells has failed in 14 patients treated worldwide to
date, suggesting inherent disease‐related defects in the stem cell
pool (Grez et al, 2011). Nonetheless, all patients showed clear
signs of improvement in their clinical conditions early after
treatment as documented by the elimination of recurrent, drug
resistant infections and reconstitution of superoxide production
at therapeutic levels. However, in four patients (two adults in
Frankfurt and two children in Zurich) a clonal outgrowth of
gene‐modiﬁed cells was observed 5–15 months after gene
therapy. This resulted in the development of a myelodysplastic
syndrome (MDS), a pre‐leukaemic condition, together with
monosomy 7 in three out of the four patients. Clonal dominance
was caused by insertional activation of two cell growth
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et al, 2006; Stein et al, 2010; and J. Reichenbach, Zurich,
personal communication). While both children were rescued by
allogeneic HSCT and are currently disease‐free, both adults
succumbed to their underlying disease and leukaemia
development.
For the treatment of WAS, gene therapy trials were initiated in
Germany in 2007. Excellent reconstitution of WAS protein
(WASp) expression was detected in multiple haematopoietic
lineages with a clear selective advantage for gene corrected
lymphocytes.Resolution ofbleeding and eczema correlated with
WASp expression concomitant with recovery from autoimmu-
nity (Boztug et al, 2010). Similarly, to the X‐CGD gene therapy
trial,the WAStrial wasinitially considered ashining examplefor
successful gene therapy, until leukaemia developed. The ﬁrst
case of T‐ALL, again triggered by insertional activation of LMO2,
was reported in 2010 (Persons & Baum, 2011). Additional
leukaemia cases were recently reported (Aiuti et al, 2012;
Mukherjee & Thrasher, 2013).
Thus, the need to establish protocols considering the speciﬁc
disease context was emphasized by the different outcomes
observed among the distinct PIDs. Disease‐related predisposi-
tionfortransformationishighlighted byretroviralintegrationsin
the same hotspot (LMO2) in trials addressing SCID‐X1, WAS and
ADA, with >30% of patients developing T‐cell leukaemia in
SCID‐X1 and WAS, compared to ADA‐SCID, in which no signs of
transformation have been observed after more than 14 years
of follow‐up (as reviewed in (Cavazza et al, 2013; Fischer
et al, 2011)). In line with this, the patient’s age, the dose of
modiﬁed cells and the numberofintegrated vectorcopies as well
as the therapeutic transgene and its regulation might require
individual adjustments. For example, the engraftment failure in
CGD patients may require regulated gene expression of the
gp91
phox protein, as inappropriate expression may induce ROS
production in HSC with enhanced differentiation and loss of
stemness (Ito et al, 2004, 2006; Juntilla et al, 2010).
In addition, the vector‐dependent leukaemia cases empha-
sized the need for enhanced vector safety, and the development
of paradigmatic in vitro and in vivo assays to prospectively
evaluate the safety proﬁle of integrating vectors (Corrigan‐Curay
et al, 2012; Modlich et al, 2006, 2009; Montini et al, 2009;
Schambach et al, 2013). In contrast to conventional allogeneic
HSCT, monitoring chimerism and clonal outgrowth of the
transplanted gene‐modiﬁed cells can be accomplished by
sequencing and tracing integration sites, thus allowing for an
estimation of the abundance of unique clones contributing to
gene‐marked haematopoiesis (Arens et al, 2012; Brugman
et al, 2013). Currently, identiﬁcation of the clonal repertoire
and monitoring of gene‐marked cells is simpliﬁed, accelerated
and rendered more sensitive by next generation sequencing
methods allowing early detection of clonal dominance making
an early intervention possible before the development of side
effects. The understanding of the molecular and cellular basis of
clonal imbalance has led to improvements especially in vector
design and several clinical trials evaluating these improved
vectorshavebeenopenedrecentlyorareunderwayasdiscussed
below in more detail.
Integrating vectors, risk of insertional
transformation and improved vector design
The severe adverse events observed in the early gene therapy
trials using gammaretroviral vectors prompted extensive studies
on the process of retroviral integration in human cell lines and
primaryhuman HSCs(CD34
þ)(Cattoglio etal,2007;Deichmann
et al, 2011; Derse et al, 2007; Mitchell et al, 2004). These studies
revealed that gammaretroviral vectors tend to integrate into
close proximity to gene regulatory regions (promoters,
enhancers, locus control regions) implying a high risk of
transcriptional dysregulation, especially since the vector con-
ﬁgurations used in these early trials contained an intact 50 long
terminal repeat (LTR), including strong enhancer and promoter
elements, which were initially intended to increase therapeutic
efﬁcacy. Moreover, the discovery of hot spot regions for
retroviralintegrationaugmentedtheprobabilityofdysregulation
of gene expression. This was indeed the case in the SCID‐X1 and
X‐CGD trials, in which a strong increase in either LMO2 or EVI1
expression was observed due to insertional activation of these
genes at their genomic loci leading to clonal dominance and
leukaemogenesis (Hacein‐Bey‐Abina et al, 2003; Ott et al, 2006).
Indeed the genomic loci for MDS‐EVI1 and LMO2 are currently
knowntobeintegration hot‐spotsforgammaretroviralvectorsin
murine and human HSCs (Cattoglio et al, 2010; Kustikova
et al, 2005). These and further observations led to the
development of the self‐inactivating (SIN) retroviral vector
design with deletions in the U3 region of the 50LTR resulting in a
transcriptionally inactive LTR. The lack of promoter activity is
compensated by an internal heterologous promoter driving the
transgene expression (as reviewed in (Maetzig et al, 2011;
Schambach et al, 2013)). Although the SIN conﬁguration is not
known to alter the integration proﬁle of gammaretroviral
vectors, the genotoxicity of vectors containing internal cellular
or tissue speciﬁc promoters is strongly reduced as measured by
the potential of these vectors to induce transformation in an
in vitro immortalization assay (Modlich et al, 2006). Indeed,
expression driven by mammalian promoters conferring more
physiological levels of expression revealed reduced incidence
or even absence of proto‐oncogene activation (Zychlinski
et al, 2008).
In contrast to gammaretroviral vectors, lentiviral vector
insertion sites are rather underrepresented in regulatory regions
but revealed a preference for integration into the body of genes.
This lowers, but does not completely alleviate, the risk of
genotoxicity according to studies addressing the oncogenic
potential of these vectors either in vitro or in vivo (Modlich
et al, 2009; Montini et al, 2006, 2009). The common consensus
drawn by these studies is that viral vector integration is an active
process catalysed by the tethering of the viral preintegration
complex to open chromatin regions in the host cell genome as
characterized by DNaseI hypersensitive sites and epigenetics
marks (Cattoglio et al, 2010; Deichmann et al, 2011; Felice
et al, 2009). For example, the host‐cell encoded LEDGF/p75
binds to the lentiviral integrase to direct integration to active
transcription units. Lentiviral vector integration can be
retargeted to heterochromatin regions in the genome by fusing
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heterochromatin‐bindingprotein1b(CBX1;Gijsbersetal,2010).
Thesestudiesalsodemonstratedthatotherretroviralvectorsand
gene delivery systems such as transposons possess an almost
neutral integration proﬁle ab initio, that could be considered to
be favourable in terms of genotoxicity. Consequently, foamy
virus and more recently alpharetrovirus derived vectors have
been evaluated in preclinical settings for PIDs since they
revealed the least biased integration preferences (Chatziandreou
et al, 2011; Derse et al, 2007; Kaufmann et al, 2012; Suerth
et al, 2012). For the same reasons, DNA transposon‐based
vectors, like Sleeping Beauty and piggyBac, have received
considerable attention in the past and are currently under
evaluation for gene replacement therapy in a series of
applications including HSC, mesenchymal stem cells and
myoblasts,amongothers.IndeedtheSleepingBeautytransposon
vector system was used to introduce CD19‐speciﬁc CARs into
T cells for the treatment of B‐cell malignancies in a Phase I/II
clinical trial initiated in 2012 (for a comprehensive review on the
Sleeping Beauty gene transfer system see (Aronovich et al, 2011;
Di Matteo et al,2012; Hackett et al, 2013; Swierczek et al, 2012)).
In addition to integration, the particular therapeutic gene
delivered, the extent of engraftment and the underlying disease
might also inﬂuence the susceptibility to cellular transformation
(Cavazza et al, 2013; Kustikova et al, 2009b). Whether these
mentioned possible scenarios ultimately result in the develop-
ment of an oncogenic process depends strongly on the cell type
affected (Kustikova et al, 2009a; Newrzela et al, 2008). Highly
proliferative cells, such as progenitor cells, are more prone to
transformation by aberrant gene expression of proto‐oncogenes
or tumour suppressor genes than terminally differentiated cells.
Taken together, vector–chromatin interaction and its con-
sequences have become more predictable, but vector‐induced
leukaemogenesis remains an unpredictable factor in gene
therapy due to its multifactorial nature as described above.
However, potential adverse effects have to be balanced against
the clinical beneﬁt expected for the individual patient, taking
into consideration the clinical complications associated with
alternative treatment options, i.e. allogeneic HSCT from a
mismatched donor. Indeed, the success and feasibility of gene
therapy is undeniable considering that the majority of the more
than 60 patients treated for ADA‐SCID and SCID‐X1 within the
last two decades experienced a clear clinical beneﬁt. Despite the
occurrence of leukaemia in some of these patients the overall
success rate of gene therapy outperforms the results obtained
after allogeneic HSCT with HLA‐mismatched donors.
The new era of gene therapy
The concept of the SIN conﬁguration greatly improved the safety
proﬁle of integrating vectors. Notsurprisingly, this conﬁguration
in combination with physiological or tissue restricted internal
promotershasalready enteredtheclinical arenawithSINvector‐
based trials (Fig 3). Indeed a SIN gammaretroviral vector
harbouring the elongation factor short (EFS) promoter driving
the expression of ILR2G is currently being evaluated in a
multicentreclinicaltrialforSCID‐X1.Todate,eightpatientshave
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Figure 3. HSC gene therapy timeline. History of gene therapy and the milestones that contributed to the implementation of gene therapy for monogeneic
disorders using haematopoietic cells (adapted from Appelbaum, 2007; Wirth et al, 2013). Milestones in HSCT are highlighted in light blue whereas major
contributions in the ﬁeld of gene transfer are coloured violet. Although no haematological disorder can be treated with Glybera (dark blue), its market approval is
a milestone for the entire ﬁeld of gene therapy. BMT, bone marrow transplantation; disease abbreviations as in the text.
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US. Although the follow up is relatively short, the initial
observations are promising according to kinetics of T lympho-
cyte reconstitution with partial restoration of humoral immunity
mimicking the results seen in the previous trial with LTR‐driven
vectors but without any sign of leukaemogenesis (Mukherjee &
Thrasher, 2013). Similarly, a SIN‐gammaretroviral vector was
recently approved in Germany for the treatment of CGD. In this
case, the vector contains a short myeloid‐speciﬁc promoter
derivedfromthe human c‐FES genecontrolling theexpression of
a codon‐optimized gp91
phox cDNA (Loew et al, 2010; Moreno‐
Carranza et al, 2009). However, SIN‐lentiviral vectors are
currently the preferred tool for transferring genes into HSCs
(Fig 3), since they possess certain advantageous attributes
compared to the gammaretroviral vectors used in the early gene
therapy trials (as reviewed in (Naldini, 2011)). Importantly, the
preintegration complex of lentiviruses is actively translocated
intothenucleusandthereby facilitatesefﬁcient transductionofa
variety of non‐dividing cells. In contrast, other retroviruses such
as gammaretroviruses depend on dissolution of the nuclear
membrane during mitosis for delivering their cargo into the
target cell nucleus. Consequently, efﬁcient transduction of HSCs
can be achieved with SIN‐lentiviral vectors after a shorter
incubation time in vitro, preserving to some extent the
physiological nature of HSCs and their engraftment potential.
Moreover, lentiviral vectors can be easily pseudotyped with
envelopes containing vesicular stomatitis virus glycoproteins
(VSVg) providing a broad tropism and enabling effective
transduction of target cells such as CD34
þ HSC. The VSVg
envelope enables robust manufacturing and puriﬁcation proto-
cols, which contribute to a superior pharmaceutical quality of
these vectors (Merten et al, 2011).
Phase I/II clinical trials with SIN‐lentiviral vectors have been
initiated for several PIDs (WAS, ADA‐SCID, CGD) as well as for
non‐PID defects amenable to treatment by gene modiﬁed HSCs,
including X‐linked adrenoleukodystrophy (X‐ALD), metachro-
matic leukodystrophy (MLD) and b‐thalassaemia.
The most advanced of these studies are the WAS Phase I/II
studiesongoingin theUK, France,Italy and theUS with atotal of
10 patients treated (A. Galy, Evry, personal communication;
Aiuti et al, 2013; Hacein‐Bey‐Abina et al, 2013). In this case, a
SIN‐lentiviral vector containing a 1.6kb stretch of the WAS
gene’s upstream regulatory region was used to drive WAS
transgene expression (Aiuti et al, 2013; Charrier et al, 2006;
Marangoni et al, 2009; Rivat et al, 2012; Scaramuzza et al, 2013).
Unlike the gammaretroviral vector used in the ﬁrst WAS gene
therapy trial, this lentiviral vector provides physiological
regulation of the WAS transgene expression in haematopoietic
cells. Patients treated with autologous HSC transduced with the
WAS lentiviral vector show restoration of WAS protein
expression in multiple lineages of leukocytes which led to
increased platelet counts, enhanced immune functions and
amelioration of the clinical manifestation of the disease (Aiuti
et al, 2013; Hacein‐Bey‐Abina et al, 2013). Similarly, a Phase I/II
trial with a SIN‐lentiviral vector for the treatment of ADA‐SCID is
ongoing in the UK and in the US (NCT01380990). Four patients
have thus far been treated with a vector containing the EF1a
promoter driving the expression of the ADA cDNA. With less
than a year of follow‐up, no conclusive statements can be made
at this time point (Gaspar et al, 2013; Zhang et al, 2013).
For X‐CGD, a Phase I/II clinical study using a SIN‐lentiviral
vector was recently approved in the UK and is currently under
regulatory review in Germany and Switzerland. As the
functional defect in CGD affects terminally differentiated
myeloid cells, attempts were made to target gene expression
to this cell population. Promoters derived from endogenous
sequencesofpredominantly myeloidexpressedgenes,e.g.MRP8
c‐FES or hsa‐miR‐223, showed speciﬁcity in vitro as well as
in vivo. However, their activity in vivo was rather weak (Brendel
et al, 2011, 2013; Heydemann et al, 2000). Therefore, several
groups addressed this challenge by fusing promoter elements of
myeloid restricted genes with other regulatory sequences, e.g.
the strong viral CMV promoter, regulatory sequences of another
myeloid expressed gene (Cathepsin G) or a ubiquitously acting
chromatin opening element (UCOE), respectively (Barde
et al, 2011; Brendel et al, 2011; Santilli et al, 2011). For
X‐CGD, the CathepsinG/c‐FES promoter combination was
selected from a series of combinations tested as the most
efﬁcient myeloid‐speciﬁc promoter to drive gp91
phox expression
in terminally differentiated myeloid cells. Indeed, pre‐clinical
trials showed excellent tissue restricted expression with low or
undetectable expression in stem and progenitor cells while
rescuing superoxide production in granulocytes to wild type
levelsatlowvectorcopynumbers(Santilli etal,2011).Targeting
gene expression to terminally differentiated myeloid cells can be
further enhanced by incorporating microRNA (miR) target
sequences into the vector backbone. In this case, residual
transcripts arising from the myeloid promoters in off‐target cells,
like HSCs or haematopoietic progenitors, are degraded by miRs
differentially expressed in HSCs and progenitor cells, but not in
terminally differentiated myeloid cells, as is the case for miR‐126
(Lechman et al, 2012). Indeed, the incorporation of two target
sites for miR‐126 in a lentiviral backbone led to a tight control
of gp91
phox expression in transduced haematopoietic cells
(A. Aiuti, Milan, personal communication).
The genetic modiﬁcation of HSC also offers the opportunity
for treatment of other monogenic disease entities besides PIDs,
which are also curable by HLA‐matched allogeneic HSC
transplantation. This is the case for inborn errors of metabolism
such as mucopolysaccharide disorders or lysosomal storage
disorders. Similarly, the leukodystrophies, a group of inherited
diseases characterized by defects in myelin sheath formation
and/or maintenance within the brain, spinal cord and often also
the peripheral nerves, can be treated by allogeneic HSC
transplantation depending on the stage of the disease and
patient age. The mechanisms of HSC‐mediated disease correc-
tion are based on the replacement of CNS microglia by the
progeny of the transplanted haematopoietic cells and/or by a
mechanism called ‘cross‐correction’, in which monocyte‐
derived cells secrete a therapeutic enzyme which is then
absorbed by enzyme‐deﬁcient cells in the CNS (mainly
oligodendrocytes and neurons), thereby preventing the neuro-
generative manifestation or progression of these disorders
(Byrne et al, 2012). Accordingly, gene‐modiﬁed autologous
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metabolic disorders. This was demonstrated in the ﬁrst clinical
trial using a SIN‐lentiviral vector for the correction of X‐ALD
(Cartier et al, 2009). X‐ALD is a severe cerebral demyelinating
disease with a strong and progressive neurological phenotype
due to a genetic defect in the ABCD1 gene encoding for the ALD
protein, an ATP‐binding cassette transporter. The progressive
and irreversible nature of this disease warrants intervention as
early as possible to allow arrest of demyelination. This was
achieved in two treated patients 14–16 months post‐transplan-
tation of gene‐modiﬁed autologous HSC transduced with an
ABCD1 expressing lentiviral vector. Since then the demyelin-
ation process has not progressed (overall follow‐up 4 years).
Most likely, this therapeutic effect was enhanced by precondi-
tioning the patients prior to the transplantation of the gene‐
modiﬁed cells, as preclinical studies have demonstrated that
preconditioning might not only facilitate efﬁcient engraftment of
gene‐transduced cells in the bone marrow but might have also
beneﬁcial effects in endogenous microglia turn over (Capotondo
et al, 2012). Since the overall outcome was successful and
10–11% gene modiﬁed cells already showed therapeutic effects
comparable to or even better than those obtained after
conventional HSCT, two more patients have been enrolled in
this trial (Cartier et al, 2009). Following the same concept, a
clinical gene therapy study for MLD, a demyelinating lysosomal
storage disorder resulting from arylsulphatase A (ARSA)
deﬁciency was initiated in 2010 in Milan. ARSA overexpression
was demonstrated throughout the haematopoietic lineages and
in the cerebrospinal ﬂuid resulting in substantial therapeutic
effect with no disease progression in any of the eight infantile
patients treated (Bifﬁ et al, 2013; Montini et al, 2013).
Treatment of b‐haemoglobinopathies, one of the most
prevalent group of inherited disorders worldwide, has been in
the interest of gene therapy for many years. However, the
formidable challenges associated with the temporal and tissue
restricted expression of the b‐globin gene have delayed the
translation of basic research into the clinic. Despite this, gene
therapy for b‐thalassaemia caused by b‐globin deﬁciency was
started in 2007. The SIN‐lentiviral vector used in this study
contained a mini‐globin gene with its introns and the 30‐
enhancerregion,aminimalversionoftheb‐globinpromoterand
locuscontrolregionandtwocopiesofthe250‐bpcoreelementof
the cHS4 chromatin insulator. An adult patient was transplanted
with ex vivo gene modiﬁed HSCs and became independent of red
blood cell transfusions 1 year later. However, most of the
therapeutic beneﬁt was associated with the expansion of a
myeloid‐restricted cell clone, in which lentiviral vector integra-
tion caused the induction of a stable, aberrantly spliced form of
the tumour suppressor gene HMGA2 leading to benign clonal
expansion (Cavazzana‐Calvo et al, 2010). In a similar study
recently opened in the US, a lentiviral vector containing the full‐
length b‐globin gene including its locus control region was used.
Twopatientshavebeentreatedtodate,howevertheobservation
time post‐transplantation is currently too short to make any
conclusive statements (Boulard et al, 2013).
With the exception of the b‐thalassaemia study mentioned
above, one common observation made in all clinical trials in
which lentiviral vectors were used, is the high repertoire of
clones contributing to gene marked haematopoiesis in bone
marrow CD34
þ cells and peripheral blood myeloid, T and B cells
oftreated patients.For example,intheWAS trials,high numbers
of unique insertions were found in peripheral blood cells in
patients over time and no signs of sustained expansion of
individual clones were observed so far. In the Italian WAS study,
33,363 unique insertions with different clones contributed to
gene‐marked haematopoiesis throughout time (last point
analysed 18 months after gene therapy; Aiuti et al, 2013).
Similarly, integration site analysis of three patients in the MLD
trial showed a polyclonal pattern of gene marking up to the last
time point analysed (18 months after gene therapy) with no
concerning events despite high gene‐marking levels in vivo in
the range between 45 and 80% (Bifﬁ et al, 2013). Lastly, a highly
diverse clonal repertoire was observed in the lentiviral X‐ALD
clinical trial as estimated from the analysis of 21,000 unique
integration sites up to 62 months follow‐up. Moreover, the
detection of common integration sites in myeloid and lymphoid
lineages argues for efﬁcient transduction of HSCs or multipotent
progenitors (Bartholomae et al, 2013). Although the observation
time in most of the above mentioned trials is relatively short, the
lack of clonal outgrowth together with the impressive clinical
beneﬁts observed in most if not all of the treated patients and the
lackoftransplantation‐relatedsideeffectsisclearevidenceofthe
power of gene therapy for the treatment of monogenic diseases
and may be favoured in the near future for the treatment of
patients lacking suitable HSC donors.
In addition to their use in ex vivo gene therapy, lentiviral
vectors have also been used in vivo particularly for the treatment
of central nervous system pathologies such as Parkinson’s
disease and ocular diseases such as the wet form of macular
degeneration, Stargardt’s disease and Usher syndrome type 1B
(http://www.oxfordbiomedica.co.uk/clinical‐trials‐1/). There
are several challenges with the use of lentiviral vectors in vivo,
for instance the need to manufacture highly‐concentrated and
highly‐puriﬁed particles, which could be facilitated by the use of
stable producer cell lines (Stewart et al, 2010). In addition,
because lentiviral vectors are integrating vectors, it is important
to reduce the off‐target delivery of these vectors in vivo. Novel
approaches for cell targeting with engineered lentiviral vector
envelope pseudotypes are exciting new developments in this
ﬁeld (Anliker et al, 2010; Frecha et al, 2012; Zhou &
Buchholz, 2013).
Of note, lentiviral vectors can be made non‐integrating
by generating integration‐deﬁcient lentiviral vectors (IDLV)
resulting in extrachromosomal DNA circles after reverse
transcription as (reviewed in (Banasik & McCray, 2009; Mátrai
et al, 2010)). This system is highly attractive for gene transfer in
post‐mitotic tissues as nicely demonstrated by Yañez‐Muñoz
et al, who used IDLV to introduce the human RPE65 gene into
the retina of a mouse model for Leber congenital amaurosis
(Yáñez‐Muñoz et al, 2006). However, the levels of expression
and transduction efﬁciency from IDLV vectors are generally low.
Nevertheless, IDLV could be very useful in settings where only
transient transgene expression is required, as for instance in
vaccination approaches or for the delivery of transposases or
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(Apolonia et al, 2007; Hu et al, 2010; Lombardo et al, 2007).
However, integrase‐independent random integration can still
occur, but at a comparatively low frequency (<10
 3; Ebina
et al, 2012; Mátrai et al, 2010).
Alternatives to integrating vectors: AAV‐derived
vectors
AAV vectors are currently considered as the delivery tool of
choice for in vivo therapy for treating inherited diseases of post‐
mitotic tissues. In contrast to lenti‐ and retroviral vectors, AAV
vectors possess a non‐enveloped protein capsid and a DNA
genome either as single‐stranded (native conformation) or as
self‐complementary DNA (artiﬁcial conformation). The latter
fold into a double‐stranded conformation by intra‐molecular
base pairing upon being released from the viral capsid leading to
a signiﬁcantly higher level and faster onset of transgene
expression compared to vectors delivering single‐stranded
vector genomes. However, this advantage comes at the price
of reducing the coding capacity from approximately 5 to 2.5kb
(McCarty et al, 2003). One of the most interesting features of the
parental virus, the replication‐deﬁcient, non‐pathogenic AAV, is
the ability to integrate its genome at a speciﬁc site on human
chromosome 19 (19q13.3‐qter, AAV integration site 1, AAVS1;
Büning et al, 2008). The viral packaging signals (inverted
terminal repeats, ITRs) ﬂanking the genome and the viral
speciﬁc non‐structural Rep proteins are required for site‐speciﬁc
integration. AAV vectors currently in use are, however, gutless
vectors, i.e. devoid of all viral open reading frames, and thus
remain pre‐dominantly in an episomal form. Therefore, AAV is
considered as a non‐integrating vector system. As a conse-
quence, long‐term correction is restricted to post‐mitotic tissue,
thus explaining the clinical focus on retina (reviewed in
(McClements & MacLaren, 2013), central nervous system
(Kaplitt et al, 2007; Leone et al, 2012), liver (reviewed in
(Mingozzi & High, 2013)), skeletal and cardiac muscle as target
tissues (Kratlian & Hajjar, 2012; Tilemann et al, 2012). While
initial studies exploited the prototype AAV serotype 2 vector,
the portfolio of AAV vectors has recently been expanded to
include additional serotypes and even engineered capsids
(Mendell et al, 2010; Mingozzi & High, 2013). Despite their
episomal nature, AAV vector genomes can be found integrated
in the genome of target cells with a frequency of 10
 4–10
 5 with
no preference for speciﬁc genomic loci, although AAV integra-
tion site hot‐spots with sequence homology to the human
mitochondrial DNA genome were recently reported (Kaeppel
et al, 2013; Nowrouzi et al, 2012).
The ﬁrst gene therapy for an inherited eye disease was
reported by three independent clinical trials in 2008 in patients
with Leber’s congenital amaurosis (LCA), an early onset retinal
dystrophy (Bainbridge et al, 2008; Hauswirth et al, 2008;
Maguire et al, 2008). In these cases, LCA was caused by
mutations in retinal pigment epithelium‐speciﬁc protein 65kDa
(RPE65) gene that encodes a retionoid isomerase (Maguire
etal,2008;McClements&MacLaren,2013).AsisomeraseRPE65
is a key factor of the retinol metabolism and hence of the visual
cycle. Owing to the need of continuous supply of 11‐cis‐retinal
for function and survival, mutations in RPE65 results in
dysfunction and degeneration of photoreceptors and thus in
loss of vision (Cideciyan et al, 2013). Overexpression of a
functional copy of RPE65 following subretinal injection of AAV2
vectors was well‐tolerated and led to improvements in vision.
The three trials mainly differed in the promoter, i.e. expression
was either controlled by the cell type speciﬁc hRPE65 promoter
(Bainbridge et al, 2008) or by a ubiquitously active promoter
(Hauswirth et al, 2008; Maguire et al, 2008). The increase
in safety by utilizing a cell type speciﬁc promoter frequently
comes at the prize of a lower expression level and this was
suggested to be responsible for the lower efﬁcacy reported by
Bainbridge et al compared to the other two studies, as high
expression levels appear to be required for vision improvement
in the elderly (Bainbridge et al, 2008; McClements &
MacLaren, 2013).
A further interesting ﬁnding concerns the immune system. In
contrast to liver‐ and muscle‐directed gene therapy trials, in
whichreactivation ofmemoryT‐cellresponses resulted inloss of
vector‐modiﬁed cells and thus attenuated therapeutic efﬁcacy
(Manno et al, 2006; Mendell et al, 2010), subretinal injection of
AAV vectors mounted only low humoral immune responses. As
all three trials had shown good safety, low immunogenicity,
goodtolerability and clinical beneﬁt, treatment of thesecond eye
has started and a number of further gene therapy trials for
inherited retinal diseases have been launched or are already
ongoing (for further details McClements & MacLaren, 2013). In
particularforthefollowupstudiesfocusingonRPE65‐associated
LCA, a recent ﬁnding by Cideciyan et al is of importance
(Cideciyan et al, 2013). Measuring the outer photoreceptor
nuclear layer thickness in treated and untreated eyes
revealed that although a lasting improvement in vision was
achieved by RPE65 overexpression, photoreceptor degeneration
continued. Hence, it seems that besides RPE65 overexpression
further interventions are required to counteract the two
pathological mechanisms, dysfunction and deregulation
of photoreceptors, in order to cure RPE65‐associated LCA
(Cideciyan et al, 2013).
Similarly to the LCA studies, unilateral local injection of AAV2
vectors expressing glutamic acid decarboxylase (GAD) into the
subthalamic nucleus of patients with advanced Parkinson’s
diseaseledtoimprovementsinclinicalscores(Kaplittetal,2007;
LeWitt et al, 2011). Consequently, a double‐blind, sham‐surgery
controlled, randomized trial with 66 patients was launched.
Again, AAV2 vectors encoding GAD were applied into the
subthalamic nucleus, however, this time bilaterally. Again,
safety and tolerability was proven. Furthermore, compared to
the sham‐surgery treated group, clinical beneﬁt for AAV2‐GAD‐
treated subjects was reported, including improved motor scores
or reductions in measures of overall severity of the disease
(LeWitt et al, 2011). A second neurodegenerative disorder, in
which gene therapy was shown to be safe and to improve
clinical scores, is Canavan disease. Speciﬁcally, the aspartocy-
lase gene (ASPA) encoding an enzyme required to degrade
N‐acetyl‐aspartate (NAA) was delivered to the brain by
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in the brain, which approached normal levels, a stabilization of
brain atrophy was observed (Leone et al, 2012).
The ﬁrst clinical trial for haemophilia B employed intra‐
muscular injections (Kay et al, 2000), a clinically well‐
established delivery route for conventional therapeutics. A
furtherclearadvantageofmuscleastargettissueisthelowerrisk
of vector dissemination compared, e.g. with liver and the ﬁnding
that pre‐existing anti‐AAV humoral immunity, a frequent
challenge for AAV‐mediated gene therapy, does not block
transduction (reviewed in Mingozzi & High, 2013). However,
multiple injections are required for delivering the pre‐deﬁned
vector dose and—based on animal studies—the risk of triggering
immune responses towards the transgene products is
higher compared with liver (Mays & Wilson, 2011). The latter
issue was considered by restricting enrollment to patients with
haemophilia B caused by missense mutations. Although a
therapeutically relevant level of factor IX was not obtained
presumably due to the relatively low secretion efﬁcacy of muscle
ﬁbres and/or the vector dose (reviewed in Mingozzi &
High, 2013), this study clearly demonstrated safety and
applicability, thus paving the way for further muscle‐directed
genetherapytrials.BychangingfromAAV2toAAV1vectorsand
by exploiting a natural‐occurring gain‐of‐function mutant of
lipoprotein lipase,
S447XLPL, a Caucasian variant naturally
associated with enhanced removal of lipoprotein particles from
thecirculation,researchers successfully overcamethiscaveatfor
LPLD (Kastelein et al, 2013).
In addition to skeletal muscle, heart muscle has also become a
target tissue for gene therapy in light of the increasing incidence
of cardiovascular diseases. Although pre‐clinical research on
developing optimized AAV vectors for the heart is still ongoing
(Yang & Xiao, 2013), results of calcium upregulation by
percutaneous administration of gene therapy in cardiac disease
(CUPID) indicate that AAV1 vectors, the same serotype as for
LPLD, successfully and safely transduce human cardiac tissue
following antegrade epicardial coronary artery infusion (Jessup
et al, 2011). CUPID was launched in the US in 2008 (Kratlian &
Hajjar, 2012) to treat patients with advanced heart failure by
overexpression of the sarcoplasmic reticulum calcium ATPase
pump (SERCA2a). SERCA2a was chosen as a target because
expression of this protein, which is essential for calcium
homeostasis, is decreased in heart failure leading to elevated
end‐diastolic calcium (Ca) levels, prolonged Ca re‐uptake
and a decrease in systolic calcium. In addition to the decreased
expression levels, conditions in failing heart negatively
impacts on the function of the remaining SERCA2a (reviewed
in Kratlian & Hajjar, 2012). AAV1‐mediated overexpression
of SERCA2a, ﬁrst assayed within an open‐label Phase I
trial, demonstrated safety as well as clinical beneﬁt in several
of the patients. Based on these results a Phase II trial with
39 patients was designed (Jessup et al, 2011; Tilemann
et al, 2012). Patients were randomly assigned to receive either
a low, middle or high vector dose or placebo. All vector‐treated
patients exhibited a decreased frequency of cardiovascular
events (Tilemann et al, 2012). In particular, the high‐dose
group met the pre‐speciﬁed success criteria, which included
decreased heart failure symptoms, improved functional
status, left ventricular function/remodelling and clinical out-
come (Jessup et al, 2011), again strongly arguing for a clinical
beneﬁt of AAV1.SERCA2a in patients with advanced heart
failure.
Since insufﬁcient levels of factor IX secretion were obtained
when choosing muscle as target tissue, High and colleagues
focused subsequently on liver, which possesses a signiﬁcant
greater capacity for secretion of factorsto thecirculation (Manno
et al, 2006) and which is reported to trigger tolerance towards
transgene products delivered by AAV vectors (Mays &
Wilson, 2011). While therapeutic levels were achieved upon
when deliver of AAV2 vectors via the portal vein, factor IX
concentration decreased in some of the patients a few weeks
after gene therapy. This phenomenon had not been observed
in pre‐clinical studies and was explained to be due to re‐
activation of memory T cells recognizing AAV capsid proteins
(reviewedin Mingozzi &High, 2013).An alternative explanation
suggested by mouse studies is the induction of a cytotoxic T‐cell
response against an epitope produced from the factor IX
transgene upon, e.g. usage of an alternative reading frame
(Li et al, 2009).
Memory T‐cell re‐activation may have been caused when a
transient, asymptomatic liver inﬂammation occurred during
which AAV‐transduced hepatocytes were lost. Prompted by
these observations, Nathwani et al changed the vector serotype
from AAV2 to AAV8 and employed the self‐complementary
vector genome conformation (Nathwani et al, 2011). The
rationale behind this decision was the assumption that a
threshold vector particle dose is required for triggering adaptive
anti‐capsid immune responses, which can presumably be
avoided by using a serotype with lower prevalence in the
human population and with a higher transduction efﬁcacy for
liver comparedtoAAV2,andbyanimproved expression levelby
changing from single‐stranded AAV vector genomes to the self‐
complementary conformation. An additional, remarkable
change to former protocols exploited by this study is the use
of peripheral vein infusion as the application route, which
appeared to be safe and resulted in a dose‐escalation study with
clear clinical beneﬁt for the patients. Furthermore, although
immune responses were also observed, a short course of
glucocorticoids was sufﬁcient to sustain therapeutic efﬁcacy of
the gene therapy (Nathwani et al, 2011).
Reviewing AAV‐mediated in vivo gene therapy reveals a
remarkable safety and efﬁcacy record. However, relatively
high vector doses are currently required to achieve
therapeutic beneﬁt and the broad tropism—a feature shared
by all serotypes—imposes the intrinsic risk for off‐target
transduction. Capsid engineering, i.e. modiﬁcation of the viral
capsid, is employed to overcome both of these obstacles and also
holds promise for the development of vectors that can be
applied in patients with a pre‐existing anti‐AAV humoral
immunity (Büning et al, 2008). As for other viral vector
systems, AAV transcriptional as well as post‐transcriptional
strategies are under development to improve cell type
speciﬁcity or to restrict transgene expression to a certain
developmental stage.
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targeted gene correction
Despite accumulating data on improved vectors, it should be
kept in mind that none of the concepts discussed so far
completely alleviates the risk of insertional transformation
associated with the use of integrating vectors. To further reduce
this risk, approaches aiming at site‐directed gene correction are
currently under evaluation. Based on the functional dissociation
of transcription factors into a DNA‐binding domain and a
transcription regulatory domain, genetic scissors have been
developed by fusing DNA‐binding domains to the catalytic
domain of endonucleases. These designer nucleases speciﬁcally
introduce a double‐strand DNA break (DSB) at a speciﬁc locus
recruiting the DNA repair machinery to this site. If an exogenous
DNA with homologous arms tothe sequence adjacent tothe DSB
(donor DNA) is provided in trans, homologous recombination
occurs resulting in the integration of the endogenous sequences
at a speciﬁc genomic site (Fig 4). If no donor DNA is provided,
DSB are corrected by the non‐homologous end joining (NHEJ)
repair machinery creating mutations/deletions at the DSB site.
Zinc‐ﬁnger nucleases (ZFN), transcription activator like effector
nucleases (TALEN) and more recently RNA‐guided nucleases
(CRISPR/Cas9) have been engineered for this purpose (as
reviewed in Mussolino & Cathomen, 2013; Perez‐Pinera
et al, 2012). The fact that a rationally designed single guide
RNAcanrecruitacorrespondingnucleasetovirtually anyspotof
the human genome has interesting perspectives for molecular
therapies. This may facilitate the ‘vectorization’ of this strategy
and even allow ‘multiplexing’ of several independent inter-
ventions as recently demonstrated (Wang et al, 2013). These
technologies will allow site‐directed integration of a therapeutic
cassette into a deﬁned locus in the target cell, thus minimizing
dysregulation of gene expression at the integration site, while
protecting the therapeutic cassette from epigenetic effects. One
of these ‘safe harbour’ integration sites is the AAVS1 locus,
which corresponds to the common integration site of AAV,
found between exon 1 and intron 1 of the protein phosphatase 1
regulatorysubunit 12Cgene.Zinc‐ﬁngerendonuclease‐mediated
site‐speciﬁc recombination at this locus results in sustained
transgene expression with no alterations in the transcriptional
pattern of adjacent genes (Lombardo et al, 2011; Sadelain
et al, 2012). The translation of this technology into the
clinics was initially delayed by suboptimal speciﬁcity, resulting
in off‐target genotoxicity and cytotoxicity of the designer
nucleases. However, new generations of zinc‐ﬁnger nucleases
and TALEN have a signiﬁcantly improved safety proﬁle (Gabriel
et al, 2011; Mussolino et al, 2011). A multicentre clinical trial is
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Figure 4. Proposed concept of designer nuclease‐mediated correction of patient‐speciﬁc iPSC for autologous transplantation. Patient-speciﬁc iPSC can be
generated from somatic cells (e.g. ﬁbroblasts, blood cells) and reprogrammed into pluripotent stem cells as discussed in the text. Targeted gene correction can be
mediated via either zinc-ﬁnger nucleases (ZFN), transcription activator like effector nucleases (TALEN) or RNA guided-nucleases of patient-derived cells either
before or after reprogramming to iPSC. Disease-corrected somatic cells can be derived from the iPSC and reintroduced into the patient as an autologous
transplant.
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nuclease targeting the HIV‐1c o ‐receptor CCR5 to protect T cells
from new infection (Burnett et al, 2012; Perez et al, 2008). More
than 30 HIV‐patients have been treated with zinc‐ﬁnger
nuclease‐modiﬁed T cells containing a disrupted CCR5 locus,
resulting in a sustained increased in CD4 counts, most likely
resulting from long‐term maintenance of CCR5‐modiﬁed central
memory CD4 cells (Lee et al, 2013). In the future, site‐directed
integration might eventually substitute for (semi‐) randomly
integrating vectors, provided comparable gene delivery and
recombination efﬁciencies can be achieved.
The perspectives of induced pluripotent stem cells
in gene and cell therapy
Pluripotent stem cells (PSC) can differentiate into cells of all
three germ layers, including ectoderm (e.g. neurons, epidermis),
mesoderm (e.g. blood, cardiac cells, muscle) and endoderm (e.g.
pancreas, liver). Given that PSC can be generated from any
individual and as such in a patient‐/disease‐speciﬁc manner
from adult somatic cells, they create intriguing options for
disease modelling, drug testing, developmental studies and
combined gene and cell therapy.
To understand the underlying networks governing repro-
gramming fate decisions in this rapidly growing area, a number
of important studies are brieﬂy mentioned here. The ﬁrst formal
proof that mature cells can be ‘reprogrammed’ into immature
PSC was obtained in1962 by John Gurdon and coworkers, who
transferred the nucleus from a mature intestinal cell to replace
the immature cell nucleus in an egg cell of a frog. This
‘genetically’ modiﬁed egg subsequently developed into a normal
Xenopus tadpole (Gurdon, 1962). Employing a similar nuclear
transfer technique, Ian Wilmut reported in 1997 the birth of the
sheep Dolly, the ﬁrst clone produced from a somatic cell taken
from an adult mammal (Wilmut et al, 1997). Of note, Tachibana
et al demonstrated recently that human embryonic stem cells
(ESC) could be derived by somatic cell nuclear transfer
(Tachibana et al, 2013). Taken together, these studies provide
clear evidence that the cytoplasm of oocytes reprogrammed
the transplanted somatic cell nuclei to pluripotency and that
these PSC could be differentiated into a variety of cell types of
all three germ layers, and in the case of Dolly, into a living
individual.
In 2006, Shinya Yamanaka discovered the pluripotency
factors (i.e. Oct4, Sox2, Klf4, c‐Myc), which were sufﬁcient
and necessary to reprogramme mature somatic cells into so‐
called induced pluripotent stem cells (iPSC; Takahashi &
Yamanaka, 2006). This seminal ﬁnding set the stage to generate
disease‐speciﬁc human iPSC from patients’ somatic cells (Park
et al, 2008; Yu et al, 2007). Since then, a steadily growing list of
patient‐speciﬁc iPSC resembling genetic diseases with either
Mendelian or complex inheritance has been generated (Onder &
Daley, 2012). These cells create an important reservoir for
further research to elucidate disease pathologies and to develop
new therapeutic options. This is especially critical in rare
diseases, where patient material is severely limited.
Patient‐speciﬁc iPSC can be differentiated into key cell types
to identify underlying disease‐associated phenotypes and
pathologiesduringdevelopmentandinthedifferentiatedmature
progeny. These cells serve as discovery and screening platforms
to identify common signalling pathways and to discover small
molecule drugs and molecular therapies that potentially reverse
the disease phenotype.
Gene therapy represents a signiﬁcantly powerful therapeutic
option to repair the known underlying genetic causes in
monogenetic disease‐speciﬁc iPSC. As for the generation of
iPSC, many opportunities exist for genetic correction of iPSC,
includingintegrating and non‐integrating viral vectors,non‐viral
vectors (e.g. Sleeping Beauty transposon), episomal, mRNA and
protein delivery. Retroviral vectors are in particular interesting
tools for the genetic modiﬁcation of iPSC, since the introduced
therapeutic expression cassette is stably integrated into the
iPSC’s genome and transmitted to all differentiated progeny.
Thus, ideally one carefully conducted treatment should allow
the permanent correction/alleviation of disease symptoms.
Moreover, the monoclonal nature of iPSC and the screening
of potential off‐target effects by whole genome sequencing allow
for the identiﬁcation of genetically corrected iPSC meeting all
safety requirements. Also, the risks of insertional transformation
(see above) can be strongly decreased by screening for ‘safe‐
harbour’ integrations. Using this strategy, Papapetrou et al
demonstratedthat 10%ofintegrationsofalentivirallyencoded
transgene occur in safe harbours and permitted sustained globin
expression in b‐thalassaemia iPSC and their differentiated
progeny (Papapetrou et al, 2011). Similarly, correction of CGD
by targeted integration of a therapeutic cassette into the AAVS1
locus was shown to restore superoxide production in gran-
ulocytes derived from the targeted iPSC (Zou et al, 2011).
Targeted correction of the disease‐causing mutations by
homologous recombination in iPSC is well within reach and
has been demonstrated for various disease‐speciﬁc iPSC
(Nakayama, 2010; Zou et al, 2011).
The growing number of studies combining approaches for
gene and cell therapy underlines the potential of iPSC derived
strategies in disease modelling and therapeutic options.
However, improved and more reliable differentiation protocols
leading to transplantable cell types that integrate into their
natural niches in vivo, e.g. engraftable HSC, will have to be
developed (Suzuki et al, 2013). This may ultimately lead to
autologous transplants, which are compatible to the recipient’s
immune system (Fig 4; Araki et al, 2013a, b). Interestingly, a ﬁrst
clinical trial using iPSC—to be conducted in Japan—is already in
sight. In this study, Masayo Takahashi, ophthalmologist at the
RIKEN Center for Developmental Biology in Kobe, plans to use
iPSC‐derived cells for the treatment of the debilitating eye
disease age‐related macular degeneration (http://blogs.nature.
com/news/2013/02/embryo‐like‐stem‐cells‐enter‐ﬁrst‐human‐
trial.html http://www.nature.com/news/stem‐cells‐cruise‐to‐
clinic‐1.12511).
In summary, combined gene and cell therapy using iPSC
may expand our reservoir of molecular therapies and may
offer interesting perspectives for the treatment of various
disorders.
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Gene therapy is on its way to fulﬁll the early promises made just
two decades ago despite the occurrence of severe side effects
observed in the initial clinical trials. The risks associated with
gene therapy are already being successfully addressed or are the
focus of current research as presented here. Multicentre studies
andgenetherapyconsortiaarecurrentlyfavourednotonlyinthe
view of sharing resources but more importantly, to obtain more
informative and reliable data by increasing patient numbers
included in the Phase I/II clinical trials. The very recent
approvals of gene therapeutic agents for the European market
are a milestone in the ﬁeld of gene therapy and raise hope for
many patients suffering from orphan diseases as well as many
other more common illnesses. These facts reﬂect the growing
acceptancethatgenetherapymightnolongerbeconsideredonly
as an alternative therapy for terminally sick patients who failed
conventional treatment, but could also become the ﬁrst‐line
treatment for a wide variety of diseases in the near future. The
recent therapeutic successes observed in many treated patients
have encouraged pharmaceutical companies to support the
development of gene therapy including Phase I/II clinical trials
(Mavilio, 2012) (http://www.uphs.upenn.edu/news/News_
Releases/2012/08/novartis/). Their involvement will certainly
boost the transition from bench to bedside for the beneﬁt of the
patients.
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